A citation-based method for searching scientific literature

Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam Schoenfeld, Clare Keddy, Monika A Davare. Nat Rev Clin Oncol 2021
Times Cited: 37



Jessica J Lin, Alice T Shaw. J Thorac Oncol 2017
Times Cited: 126




List of shared articles



Times cited

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.
Jessica J Lin, Noura J Choudhury, Satoshi Yoda, Viola W Zhu, Ted W Johnson, Ramin Sakhtemani, Ibiayi Dagogo-Jack, Subba R Digumarthy, Charlotte Lee, Andrew Do,[...]. Clin Cancer Res 2021
12

Fusion proteins in lung cancer: addressing diagnostic problems for deciding therapy.
Federica Zito Marino, Greta Alì, Francesco Facchinetti, Luisella Righi, Gabriella Fontanini, Giulio Rossi, Renato Franco. Expert Rev Anticancer Ther 2021
3

TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors.
Emiliano Cocco, Ji Eun Lee, Srinivasaraghavan Kannan, Alison M Schram, Helen H Won, Sophie Shifman, Amanda Kulick, Laura Baldino, Eneda Toska, Amaia Arruabarrena-Aristorena,[...]. Cancer Discov 2021
16

Interstitial Deletions Generating Fusion Genes.
Ioannis Panagopoulos, Sverre Heim. Cancer Genomics Proteomics 2021
2

MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer.
Sudarshan R Iyer, Igor Odintsov, Adam J Schoenfeld, Evan Siau, Marissa S Mattar, Elisa de Stanchina, Inna Khodos, Alexander Drilon, Gregory J Riely, Marc Ladanyi,[...]. Mol Cancer Res 2022
0

Predicting Anticancer Drug Resistance Mediated by Mutations.
Yu-Feng Lin, Jia-Jun Liu, Yu-Jen Chang, Chin-Sheng Yu, Wei Yi, Hsien-Yuan Lane, Chih-Hao Lu. Pharmaceuticals (Basel) 2022
1

Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements.
Yongchang Zhang, Zhe Huang, Liang Zeng, Xiangyu Zhang, Yizhi Li, Qinqin Xu, Haiyan Yang, Analyn Lizaso, Chunwei Xu, Jun Liu,[...]. NPJ Precis Oncol 2022
0

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date.
Sébastien Gendarme, Olivier Bylicki, Christos Chouaid, Florian Guisier. Curr Oncol 2022
0

Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors.
Clare Keddy, Pushkar Shinde, Kristen Jones, Stefanie Kaech, Romel Somwar, Ujwal Shinde, Monika A Davare. Mol Cancer Ther 2022
0